期刊文献+

液相色谱-质谱联用技术鉴定奥美沙坦酯有关物质 被引量:4

Identification of related substances in olmesartan medoxomil by LC-MS/MS
原文传递
导出
摘要 目的:采用液相色谱-质谱联用技术对奥美沙坦酯中有关物质进行结构鉴定。方法:采用LiChrospher C8(250 mm×4.6 mm,5μm)色谱柱,以甲醇-醋酸铵缓冲液为流动相梯度洗脱,对奥美沙坦酯有关物质进行分离;采用LC-MS/MS电喷雾正离子化测定各有关物质的相对分子质量和二级质谱,并进行结构解析。结果:检测到奥美沙坦酯粗品中11个有关物质,并推测出它们的化学结构均为奥美沙坦母核结构未发生变化的不同取代咪唑和四氮唑联苯衍生物。结论:色谱-质谱联用技术能够有效地用于药物中有关物质的鉴定,奥美沙坦酯有关物质研究可为其质量控制和工艺优化提供参考依据。 Objective:To use hyphenated techniques for the identification of related substances in olmesartan medoxomil. Methods: An LC -MS/MS method was established by using a LiChrospher C8 (250 mm × 4.6 mm,5 μm) column with gradient elution by a mobile phase consisting of methanol and ammonium acetate buffer solution. Electrospray ionization (ESI) source was operated in positive ion mode. The parent ions and the product ions of the related substances were acquired and elucidated. Results: Eleven related substances were found in olmesartan medoxomil raw material and their structures were elucidated as the different substituents having the same frame structure as olmesartan medoxomil. Conclusion:The hyphenated LC - MS method is useful for the investigation of related substances in pharmaceuticals. The related substances found in olmesartan medoxomil are valuable for its manufacturing process and quality control.
出处 《药物分析杂志》 CAS CSCD 北大核心 2012年第1期82-87,共6页 Chinese Journal of Pharmaceutical Analysis
关键词 奥美沙坦酯 有关物质 液相色谱-串联质谱 杂质结构鉴定 优化工艺 olmesartan medoxomil related substances LC - MS/MS impurity structure identification optimum technology
  • 相关文献

参考文献4

二级参考文献24

  • 1张启明,李慧义.色谱分析中面积归一化法测定有关物质的弊与利[J].中国药品标准,2005,6(4):45-46. 被引量:14
  • 2翁水旺.反相高效液相色谱法测定奥美沙坦酯的有关物质[J].药物分析杂志,2006,26(5):686-688. 被引量:6
  • 3吴泰志,刘晓华,张福利,谢美华.抗高血压药奥美沙坦酯合成新路线和相关杂质的研究[J].药学学报,2006,41(6):537-543. 被引量:14
  • 4ZHOU Hai-jun(周海钧).International Conference on Harmonisation of Technical Requirements lbr Registration of Pharmaceuticals for Hunmn Use(药品注册的国际技术要求).Quality Topics(质量部分).Chieftranslator(主译).Beijing(北京):People’S Medical Publishing House(人民卫生出版社),2000.
  • 5MIZUNO M, SADA T, IKEDA M, et al. Pharmacology of CS-866, a novel nonpeptide angiotensin Ⅱ receptor antagonist [J ].Eur J Pharmacol, 1995, 285(2): 181-188.
  • 6KOIKE H, SADA T, MIZUNO M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin Ⅱ type AT1 receptor antagonist[J]. J Hypertens Suppl, 2001, 19 Suppl 1: S3-S14.
  • 7WARNER GT, JARVIS B. Olmesartan medoxomil [J ]. Drugs,2002,62(9) : 1345-1353.
  • 8KOIKE H. New pharmacologic aspects of CS-866, the newest angiotensin Ⅱ receptor antagonist [J ]. Am J Cardiol, 2001, 87(8A): 33C-36C.
  • 9SCHWOCHO LR, MASONSON HN. Pharmacokinetics of CS-866, a new angiotensin Ⅱ receptor blocker, in health subjects[J]. J Clin Pharmacol, 2001, 41(5):512-527.
  • 10PUCHLER K, NUSSBERGER J, LAEIS P, et al. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin Ⅱ antagonist, in salt-restricted hypertensive patients[J]. J Hypertens, 1997, 15 (12 Pt 2): 1809-1812.

共引文献27

同被引文献40

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部